BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.